Industrial, Manufacturing & Heavy Industry Market News

Bioresorbable stents market worth 417.2 million USD by 2022 according to new research report

Bioresorbable stents market worth 417.2 million USD by 2022 according to new research report

The report "Bioabsorbable Stent/Bioresorbable Scaffold Market by Material (Polymer/Metal), Absorption Rate (Slow, Fast), Application (Coronary Artery Disease/CAD, Peripheral/PAD) & End User (Hospital, Cardiovascular Center) - Global Forecasts to 2022", The global bioresorbable stents market is expected to reach USD 417.2 Million by 2022 from USD 223.6 Million in 2016, at a CAGR of 11.5% during the forecast period 2017-2022. The growth of the market is attributed to growing aging population susceptible to coronary and peripheral artery diseases, rising PCI procedures, increasing focus of companies on clinical trials of bioresorbable stents, increasing adoption of these stents by physicians and patients, and preference for minimally invasive therapies.

- Advertising -

Browse 73 Market Data Tables and 33 Figures spread through 138 Slides and in-depth TOC on "Bioabsorbable Stent/Bioresorbable Scaffold Market by Material (Polymer/Metal), Absorption Rate (Slow, Fast), Application (Coronary Artery Disease/CAD, Peripheral/PAD) & End User (Hospital, Cardiovascular Center) - Global Forecasts to 2022"
www.marketsandmarkets.com/Market-R…ket-40983380.html

Bioresorbable polymer-based stents projected to grow at the highest CAGR

Based on material, the market is segmented into bioresorbable polymer-based stents and bioresorbable metallic stents. The bioresorbable polymer-based stents segment is expected to grow at the highest CAGR during the forecast period.

The growth of this market is attributed to companies’ increasing focus on developing polymeric stents and approvals being granted for polymer-based stents across various regions

Based on applications, the coronary artery diseases are expected to dominate the market in 2017

Based on application, the market is segmented into coronary artery diseases and peripheral artery diseases.

- Advertising -

In 2017, coronary artery diseases accounted for the largest share of the market. The dominance of this segment is attributed to factors such as increasing aging population prone to coronary artery diseases and the adoption of unhealthy lifestyle habits leading to increased risk of these diseases.

Download PDF Brochure at www.marketsandmarkets.com/pdfdownload.asp?id=40983380

Europe to dominate the market during the forecast period

In 2017, Europe is expected to account for the largest share of the market. The dominance of the European market is attributed to the factors such as increasing regulatory approvals for stents which will facilitate their commercialization and rising research activities for development of bioresorbable stents.

In 2017, Asia is expected to hold the second largest share of this market. Factors such as, increasing industrial development, rising disposable income, burgeoning aging population with changing lifestyle (which have increased the prevalence of CAD), and the higher prevalence of diabetes are important factors to fuel the market growth in this region.

The bioresorbable stents screening market is a niche market with the presence of several emerging players and few big players. Prominent players in the market include Abbott (U.S.), BIOTRONIK SE & Co.

KG (Germany), REVA Medical, Inc. (U.S.), Elixir Medical Corporation (U.S.), and Kyoto Medical Planning Co., Ltd.

(Japan).

Report: www.marketsandmarkets.com/speaktoa…t.asp?id=40983380

 

News From

MarketsandMarkets™ - Business ResearchMarketsandMarkets™
Category: Market Research Publishers and RetailersCompany profile: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...